Kalie Tommerdahl, MD, MS

Dr. Kalie L. Tommerdahl is an Associate Professor of Pediatrics in the Division of Endocrinology and Diabetes at the University of Washington and Seattle Children’s Hospital on the Physician-Scientist track and serve as the Director of Clinical Trial Safety at the University of Washington Medicine Diabetes Institute. Her research focus lies in diabetes clinical and translational research with studies aimed at decreasing morbidity and mortality in individuals with diabetes through the reduction of early cardiac, vascular, and kidney complications, the leading causes of diabetes-related morbidity and mortality. Dr. Tommerdahl’s laboratory assesses pediatric and adult insulin sensitivity (IVGTT, hyperinsulinemic-euglycemic clamps, hyperglycemic clamps), kidney structure and function (p-aminohippurate clearance, iohexol clearance, MRI), cardiac structure and function (MRI, ECHO), vascular function (SphygmoCor, EndoPAT, ambulatory blood pressure monitoring), body composition (bioimpedance spectroscopy, bioelectrical impedance analysis, DXA), autonomic function (heart rate variability), and endothelial function (vascular endothelial cell biopsy). She currently serves as the principal investigator of the “MANATEE-T1D: Metformin ANd AutomaTEd insulin delivery system Effects on renal vascular resistance, insulin sensitivity, and cardiometabolic function in youth with Type 1 Diabetes” study sponsored by NIH/NHLBI and the “Effects of High-Resistance Inspiratory Muscle Strength Training (IMST) on Cardiorenal and Vascular Function” study sponsored by the American Diabetes Association (ADA). She is also a co-investigator of studies sponsored by the NIH/NHLBI, NIH/NIDDK, Breakthrough T1D, the Kidney Foundation of Canada, and the Canadian Institutes of Health Research (CIHR) including “T1-DISCO: Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes,” “ATTEMPT: Adolescent Type 1 Diabetes Treatment with SGLT2i for Hyperglycemia and Hyperfiltration Trial,” “REMODEL-T1D: Renal mode of action of semaglutide in patients with type 1 diabetes and chronic kidney disease,” and “The Sodium Glucose Co-Transport-2 Inhibition Diabetes and Kidney Function Loss in Type 1 Diabetes (SUGARNSALT).” She remains dedicated to investigating the use of novel drugs and innovative technologies for the prevention of early cardiovascular, kidney, and metabolic complications in individuals with diabetes across the lifespan.